Correspondence: Julie Maggio, PT, DPT, NCS, Department of Physical Therapy, Massachusetts General Hospital, 15 Parkman St, Boston, MA 02114 ([email protected]).
Department of Physical Therapy (J.M.), Massachusetts General Hospital, Boston; Functional Neurological Disorder Unit and Research Program (J.M., K.K., C.D.S., D.L.P.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Movement Disorders Division (C.D.S.), Dystonia Center and Ataxia Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; and Division of Neuropsychiatry (D.L.P.), Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.
David L. Perez and Julie Maggio received funding from the Sidney R. Baer Jr Foundation for participation in this manuscript. Dr Stephen has provided scientific advisory for SwanBio Therapeutics and received research funding from Sanofi-Genzyme for a study of video oculography in late-onset GM2 gangliosidosis. He has received financial support from Sanofi-Genzyme, Biogen, and Biohaven for the conduct of clinical trials. Dr Perez has received honoraria for continuing medical education lectures in functional neurological disorder and royalties from Springer Nature for a functional movement disorder textbook. Julie Maggio has received honoraria for continuing medical education lectures in functional neurological disorder. For the remaining author, no conflicts of interest were declared.
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal's Web site (www.jnpt.org).